Background: In children aged <5 years in whom severe respiratory syncytial virus (RSV) episodes predominantly occur, there are currently no appropriate standardised instruments to estimate quality of life years (QALY) loss.
Objectives: We estimated the age-specific QALY loss due to RSV by developing a regression model which predicts the QALY loss without the use of standardised instruments.
Methods: We conducted a surveillance study which targeted confirmed RSV episodes in children aged <5 years (confirmed cases) and their household members who experienced symptoms of RSV during the same time (suspected cases). All participants were asked to complete questions regarding their health during the infection, with the suspected cases additionally providing health-related quality of life (HR-QoL) loss estimates by completing EQ-5D-3L-Y or EQ-5D-3L instruments. We used the responses from the suspected cases to calibrate a regression model which estimates the HR-QoL and QALY loss due to infection.
Findings: For confirmed RSV cases in children under 5 years of age who sought health care, our model predicted a QALY loss per RSV episode of 3.823 × 10−3 (95% CI 0.492-12.766 × 10−3), compared with 3.024 × 10−3 (95% CI 0.329-10.098 × 10−3) for under fives who did not seek health care. Quality of life years loss per episode was less for older children and adults, estimated as 1.950 × 10−3 (0.185-9.578 × 10−3) and 1.543 × 10−3 (0.136-6.406 × 10−3) for those who seek or do not seek health care, respectively.
Conclusion: Evaluations of potential RSV vaccination programmes should consider their impact across the whole population, not just young child children.
Bibliographical noteFunding Information: KEA acknowledges funding from the National Institute for Health Research Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England. DH received funding from a Medical Research Council PhD Studentship (administered through CoMPLEX University College London). DT received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement #634446 for the I‐MOVE+ (Integrated MoGnitoring of Vaccines in Europe) project. JPG's research is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care North Thames at Bart's Health NHS Trust (NIHR CLAHRC North Thames). The views expressed are those of the authors and not necessarily those of the National Health Service, the Medical Research Council, National Institute for Health Research, Department of Health, European Union or Public Health England. We thank Nick Andrews for helpful advice and guidance with the statistical analyses.
Open Access: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Publisher Copyright: © 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Citation: Hodgson, D, Atkins, KE, Baguelin, M, et al. Estimates for quality of life loss due to Respiratory Syncytial Virus. Influenza Other Respi Viruses. 2020; 14: 19– 27.
- health-related quality of life
- human respiratory syncytial virus
- quality-adjusted life years
- respiratory disease